Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 1/2004

01-01-2004 | Review Article

Pharmacokinetics of Local Anaesthetics in Infants and Children

Authors: Dr Jean-Xavier Mazoit, Bernard J. Dalens

Published in: Clinical Pharmacokinetics | Issue 1/2004

Login to get access

Abstract

Amide local anaesthetics used for regional anaesthesia in paediatric patients are potent sodium channel blockers with marked stereospecificity, which consistently influences their action, especially their toxic action on the heart. At toxic concentrations, they induce severe arrhythmias with the potential for cardiac arrest. These agents are all bound to serum proteins, mainly to α1-acid glycoprotein (AAG), but also to human serum albumin. Protein binding ranges from 65% (lidocaine) to more than 95% (bupivacaine, ropivacaine). Because AAG is a major acute phase protein, its concentration rapidly increases when inflammatory processes develop, particularly during the postoperative period. Neonates and infants have a lower AAG concentration in serum as compared with adults; therefore, their free fraction of local anaesthetics is increased accordingly. This has important clinical implications since, at least at steady state, the toxic effects of local anaesthetics are directly related to the free (unbound) drug concentration.
After injection into the epidural space, absorption into the bloodstream follows a biphasic process. The buffering properties of the epidural space are important and prevent a rapid rise in concentration. In infants and children, the epidural space seems to protect patients in a similar manner. Moreover, it has been observed that the peak plasma concentration (Cmax) of ropivacaine is delayed in infants and children when compared with adults. The time to Cmax decreases from 90–120 minutes in infants aged less than 6 months to 30 minutes in children aged more than 8 years.
This delay in Cmax may also be related to the lower clearance observed in younger patients. Local anaesthetics are metabolised by cytochrome P450 (CYP). The main CYP isoforms involved are CYP3A4 for lidocaine and bupivacaine and CYP1A2 for ropivacaine. CYP3A4 is not mature at birth but is partly replaced by CYP3A7. The intrinsic clearance of bupivacaine is only one-third of that in adults at 1 month of age, and two-thirds at 6 months. CYP1A2 is not fully mature before the age of 3 years. Indeed, the clearance of ropivacaine does not reach its maximum before the age of 5 years. However, at birth this clearance is not as low as expected, and ropivacaine may be used even in younger patients.
Literature
1.
Fortuna A. Caudal analgesia: a simple and safe technique in paediatric surgery. Br J Anaesth 1967; 39: 165–70PubMedCrossRef
2.
Schulte-Steinberg O, Rahlfs VW. Caudal anaesthesia in children and spread of 1 per cent lignocaine: a statistical study. Br J Anaesth 1970; 42: 1093–9PubMedCrossRef
3.
Giaufre E, Dalens B, Gombert A. Epidemiology and morbidity of regional anesthesia in children: a one-year prospective survey of the French-Language Society of Pediatric Anesthesiologists. Anesth Analg 1996; 83: 904–12PubMed
4.
Schulte-Steinberg O, Rahlfs VW. Caudal anesthesia in children and the distribution of 0.25 per cent bupivacaine solution: a statistical study. Anaesthesist 1972; 21: 94–100PubMed
5.
Eyres RL, Kild J, Oppenheim R, et al. Local anaesthetic plasma levels in children. Anaesth Intensive Care 1978; 6: 243–7PubMed
6.
Rigler ML, Drasner K, Krejcie TC, et al. Cauda equina syndrome after continuous spinal anesthesia. Anesth Analg 1991; 72: 275–81PubMedCrossRef
7.
Lambert DH, Hurley RJ. Cauda equina syndrome and continuous spinal anesthesia. Anesth Analg 1991; 72: 817–9PubMedCrossRef
8.
Hampl KF, Schneider MC, Ummenhofer W, et al. Transient neurologic symptoms after spinal anesthesia. Anesth Analg 1995; 81: 1148–53PubMed
9.
Freedman JM, Li DK, Drasner K, et al. Transient neurologic symptoms after spinal anesthesia: an epidemiologic study of 1,863 patients. Anesthesiology 1998; 89: 633–41PubMedCrossRef
10.
Markey JR, Naseer OB, Bird DJ, et al. Transient neurologic symptoms after epidural analgesia. Anesth Analg 2000; 90: 437–9PubMed
11.
Bourlon-Figuet S, Dubousset A-M, Benhamou D, et al. Transient neurologic symptoms after epidural analgesia in a five-year-old child. Anesth Analg 2000; 91: 856–7PubMedCrossRef
12.
Flandin-Bléty C, Barrier G. Accidents following extradural analgesia in children: the results of a retrospective study. Paediatr Anaesth 1995; 5: 41–6PubMedCrossRef
13.
Bouaziz H, Okubo N, Malinovsky JM, et al. The age-related effects of epidural lidocaine, with and without epinephrine, on spinal cord blood flow in anesthetized rabbits. Anesth Analg 1999; 88: 1302–7PubMed
14.
Maxwell LG, Martin LD, Yaster M. Bupivacaine-induced cardiac toxicity in neonates: successful treatment with intravenous phenytoin. Anesthesiology 1994; 80: 682–6PubMedCrossRef
15.
Hellstrom-Westas L, Westgren U, Rosen I, et al. Lidocaine for treatment of severe seizures in newborn infants: I. clinical effects and cerebral electrical activity monitoring. Acta Paediatr Scand 1988; 77: 79–84PubMedCrossRef
16.
Satas S, Johannessen SI, Hoem NO, et al. Lidocaine pharmacokinetics and toxicity in newborn pigs. Anesth Analg 1997; 85: 306–12PubMed
17.
Kohane DS, Sankar WN, Shubina M, et al. Sciatic nerve blockade in infant, adolescent, and adult rats: a comparison of ropivacaine with bupivacaine. Anesthesiology 1998; 89: 1199–208PubMedCrossRef
18.
Brown DL, Ransom DM, Hall JA, et al. Regional anesthesia and local anesthetic-induced systemic toxicity: seizure frequency and accompanying cardiovascular changes. Anesth Analg 1995; 81: 321–8PubMed
19.
Albright GA. Cardiac arrest following regional anesthesia with etidocaine and bupivacaine. Anesthesiology 1979; 51: 285–7PubMedCrossRef
20.
de La Coussaye J, Brugada J, Allessie MA. Electrophysiologic and arrhythmogenic effects of bupivacaine: a study with highresolution ventricular epicardial mapping in rabbit hearts. Anesthesiology 1992; 77: 32–41CrossRef
21.
Mazoit JX, Decaux A, Bouaziz H, et al. Comparative ventricular electrophysiologic effect of racemic bupivacaine, levobupivacaine, and ropivacaine on the isolated rabbit heart. Anesthesiology 2000; 93: 784–92PubMedCrossRef
22.
Bardsley H, Gristwood R, Baker H, et al. A comparison of the cardiovascular effects of levobupivacaine and rac-bupivacaine following intravenous administration to healthy volunteers. Br J Clin Pharmacol 1998; 46: 245–9PubMedCrossRef
23.
Chang DH, Ladd LA, Copeland S, et al. Direct cardiac effects of intracoronary bupivacaine, levobupivacaine and ropivacaine in the sheep. Br J Pharmacol 2001; 132: 649–58PubMedCrossRef
24.
Freysz M, Timour Q, Mazze RI, et al. Potentiation by mild hypothermia of ventricular conduction disturbances and reentrant arrhythmias induced by bupivacaine in dogs. Anesthesiology 1989; 70: 799–804PubMedCrossRef
25.
Timour Q, Freysz M, Mazze R, et al. Enhancement by hyponatremia and hyperkalemia of ventricular conduction and rhythm disorders caused by bupivacaine. Anesthesiology 1990; 72: 1051–6PubMedCrossRef
26.
Freysz M, Timour Q, Bertrix L, et al. Enhancement by ischemia of the risk of cardiac disorders, especially fibrillation, in regional anesthesia with bupivacaine. Acta Anaesthesiol Scand 1993; 37: 350–6PubMedCrossRef
27.
Tucker GT, Boyes RN, Bridenbaugh PO, et al. Binding of anilide-type local anesthetics in human plasma: I. relationships between binding, physicochemical properties, and anesthetic activity. Anesthesiology 1970; 33: 287–303PubMedCrossRef
28.
Meunier JF, Goujard E, Dubousset AM, et al. Pharmacokinetics of bupivacaine after continuous epidural infusion in infants with and without biliary atresia. Anesthesiology 2001; 95: 87–95PubMedCrossRef
29.
Lönnqvist PA, Herngren L. Effects of pronounced haemodilution on the plasma protein binding of lidocaine. Perfusion 1995; 10: 17–20PubMedCrossRef
30.
Burm AG, van der Meer AD, van Kleef JW, et al. Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate. Br J Clin Pharmacol 1994; 38: 125–9PubMedCrossRef
31.
Emanuelsson BM, Persson J, Alm C, et al. Systemic absorption and block after epidural injection of ropivacaine in healthy volunteers. Anesthesiology 1997; 87: 1309–17PubMedCrossRef
32.
Lönnqvist PA, Westrin P, Larsson BA, et al. Ropivacaine pharmacokinetics after caudal block in 1–8 year old children. Br J Anaesth 2000; 85: 506–11PubMedCrossRef
33.
Mazoit JX, Denson DD, Samii K. Pharmacokinetics of bupivacaine following caudal anesthesia in infants. Anesthesiology 1988; 68: 387–91PubMedCrossRef
34.
Hansen TG, Ilett KF, Reid C, et al. Caudal ropivacaine in infants: population pharmacokinetics and plasma concentrations. Anesthesiology 2001; 94: 579–84PubMedCrossRef
35.
Kremer JMH, Wilting J, Jansen LHM. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 1988; 40: 1–47PubMed
36.
Burm AG, Cohen IM, van Kleef JW, et al. Pharmacokinetics of the enantiomers of mepivacaine after intravenous administration of the racemate in volunteers. Anesth Analg 1997; 84: 85–9PubMed
37.
Veering BT, Burm AG, Feyen HM, et al. Pharmacokinetics of bupivacaine during postoperative epidural infusion: enantioselectivity and role of protein binding. Anesthesiology 2002; 96: 1062–9PubMedCrossRef
38.
Mazoit JX, Cao LS, Samii K. Binding of bupivacaine to serum proteins, isolated albumin and isolated α1-acid glycoprotein: differences between the two enantiomers are partly due to cooperativity. J Pharmacol Exp Ther 1996; 256: 109–15
39.
Booker PD, Taylor C, Saba G. Perioperative changes in α1-acid glycoprotein concentrations in infants undergoing major surgery. Br J Anaesth 1996; 76: 365–8PubMedCrossRef
40.
Denson D, Coyle D, Thompson G, et al. Alpha 1-acid glycoprotein and albumin in human serum bupivacaine binding. Clin Pharmacol Ther 1984; 35: 409–15PubMedCrossRef
41.
Rolan PE. Plasma protein binding displacement interactions: why are they still regarded as clinically important? Br J Clin Pharmacol 1994 Feb; 37(2): 125–8PubMedCrossRef
42.
Denson DD, Mazoit JX. Physiology and pharmacology of local anesthetics. In: Sinatra RS, editor. Acute pain mechanisms and management. St Louis (MO): Mosby, 1992: 124–39
43.
Gjonaj ST, Lowenthal DB, Dozor AJ. Nebulized lidocaine administered to infants and children undergoing flexible bronchoscopy. Chest 1997; 112: 1665–9PubMedCrossRef
44.
Sitbon P, Laffon M, Lesage V, et al. Lidocaine plasma concentrations in pediatric patients after providing airway topical anesthesia from a calibrated device. Anesth Analg 1996; 82: 1003–6PubMed
45.
Day RO, Chalmers DR, Williams KM, et al. The death of a healthy volunteer in a human research project: implications for Australian clinical research. Med J Aust 1998; 168: 449–51PubMed
46.
Burm AGL, Vermeulen NPE, Van Kleef JW, et al. Pharmacokinetics of lidocaine and bupivacaine in surgical patients following epidural administration: simultaneous investigation of absorption and disposition kinetics using stable isotopes. Clin Pharmacokinet 1987; 13: 191–203PubMedCrossRef
47.
Burm AGL. Clinical pharmacokinetics of epidural and spinal anaesthesia. Clin Pharmacokinet 1989; 16: 283–311PubMedCrossRef
48.
Karmakar MK, Aun CS, Wong EL, et al. Ropivacaine undergoes slower systemic absorption from the caudal epidural space in children than bupivacaine. Anesth Analg 2002; 94: 259–65PubMed
49.
McCann ME, Sethna NF, Mazoit JX, et al. The pharmacokinetics of epidural ropivacaine in infants and young children. Anesth Analg 2001; 93: 893–7PubMedCrossRef
50.
Emanuelsson B-MK, Zaric D, Nydahl P-A, et al. Pharmacokinetics of ropivacaine and bupivacaine during 21 hours of continuous epidural infusion in healthy male volunteers. Anesth Analg 1995; 81: 1163–8PubMed
51.
Ecoffey C, Desparmet J, Berdeaux A, et al. Bupivacaine in children: pharmacokinetics following caudal anesthesia. Anesthesiology 1985; 63: 447–8PubMedCrossRef
52.
Ecoffey C, Dubousset AM, Samii K. Lumbar and thoracic epidural anesthesia for urologic and upper abdominal surgery in infants and children. Anesthesiology 1986; 65: 87–90PubMedCrossRef
53.
Murat I, Montay G, Delleur MM, et al. Bupivacaine pharmacokinetics during epidural anaesthesia in children. Eur J Anaesthesiol 1988; 5: 113–20PubMed
54.
Smith T, Moratin P, Wulf H. Smaller children have greater bupivacaine plasma concentrations after ilioinguinal block. Br J Anaesth 1996; 76: 452–5PubMedCrossRef
55.
Dalens B, Ecoffey C, Joly A, et al. Pharmacokinetics and analgesic effect of ropivacaine following ilioinguinal/iliohypogastric nerve block in children. Paediatr Anaesth 2001; 11: 415–20PubMedCrossRef
56.
Burm AG, de Boer AG, van Kleef JW, et al. Pharmacokinetics of lignocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. Biopharm Drug Dispos 1988; 9: 85–95PubMedCrossRef
57.
Veering BT, Burm AG, Vletter AA, et al. The effect of age on the systemic absorption, disposition and pharmacodynamics of bupivacaine after epidural administration. Clin Pharmacokinet 1992; 22: 75–84PubMedCrossRef
58.
Morrison LMM, Emanuelsson BM, McClure JH, et al. Efficacy and kinetics of extradural ropivacaine: comparison with bupivacaine. Br J Anaesth 1994; 72: 164–9PubMedCrossRef
59.
Weston PJ, Bourchier D. The pharmacokinetics of bupivacaine following interpleural nerve block in infants of very low birthweight. Paediatr Anaesth 1995; 5: 219–22PubMedCrossRef
60.
Desparmet J, Meistelman C, Barre J, et al. Continuous epidural infusion of bupivacaine for postoperative pain relief in children. Anesthesiology 1987; 67: 108–10PubMedCrossRef
61.
Emanuelsson BM, Persson J, Sandin S, et al. Intraindividual and interindividual variability in the disposition of the local anaesthetic ropivacaine in healthy subjects. Ther Drug Monit 1997; 19: 126–31PubMedCrossRef
62.
Burm AG, Stienstra R, Brouwer RP, et al. Epidural infusion of ropivacaine for postoperative analgesia after major orthopedic surgery: pharmacokinetic evaluation. Anesthesiology 2000; 93: 395–403PubMedCrossRef
63.
Hansen TG, Ilett KF, Lim SI, et al. Pharmacokinetics and clinical efficacy of long-term epidural ropivacaine infusion in children. Br J Anaesth 2000; 85: 347–53PubMedCrossRef
64.
Iida H, Watanabe Y, Dohi S, et al. Direct effects of ropivacaine and bupivacaine on spinal pial vessels in canine: assessment with closed spinal window technique. Anesthesiology 1997; 87: 75–81PubMedCrossRef
65.
Iida H, Ohata H, Iida M, et al. The differential effects of stereoisomers of ropivacaine and bupivacaine on cerebral pial arterioles in dogs. Anesth Analg 2001; 93: 1552–6PubMedCrossRef
66.
Burm AGL, Van Kleef JW, Gladines MPRR, et al. Epidural anesthesia with lidocaine and bupivacaine: effects of epinephrine on the plasma concentration profiles. Anesth Analg 1986; 65: 1281–4PubMedCrossRef
67.
Warner MA, Kunkel SE, Offord KO, et al. The effects of age, epinephrine, and operative site on duration of caudal analgesia in pediatric patients. Anesth Analg 1987; 66: 995–8PubMedCrossRef
68.
Doyle E, Morton NS, McNicol LR. Plasma bupivacaine levels after fascia iliaca compartment block with and without adrenaline. Paediatr Anaesth 1997; 7: 121–4PubMedCrossRef
69.
Hansen TG, Morton NS, Cullen PM, et al. Plasma concentrations and pharmacokinetics of bupivacaine with and without adrenaline following caudal anaesthesia in infants. Acta Anaesthesiol Scand 2001; 45: 42–7PubMedCrossRef
70.
Mather LE. Anatomical-physiological approaches in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2001; 40: 707–22PubMedCrossRef
71.
Luz G, Innerhofer P, Haussler B, et al. Comparison of ropivacaine 0.1% and 0.2% with bupivacaine 0.2% for single-shot caudal anaesthesia in children. Paediatr Anaesth 2000; 10: 499–504PubMedCrossRef
72.
Hines RN, McCarver DG. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 2002; 300: 355–60PubMedCrossRef
73.
Tateishi T, Nakura H, Asoh M, et al. A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. Life Sci 1997; 61: 2567–74PubMedCrossRef
74.
Tanaka E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther 1998; 23: 247–55PubMedCrossRef
75.
Kuhnert BR, Zuspan KJ, Kuhnert PM, et al. Bupivacaine disposition in mother, fetus, and neonate after spinal anesthesia for cesarean section. Anesth Analg 1987; 66: 407–12PubMed
76.
Gantenbein M, Attolini L, Bruguerolle B, et al. Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab Dispos 2000; 28: 383–5PubMed
77.
Oda Y, Furuichi K, Tanaka K, et al. Metabolism of a new local anesthetic, ropivacaine, by human hepatic cytochrome P450. Anesthesiology 1995; 82: 214–20PubMedCrossRef
78.
Ekstrom G, Gunnarsson UB. Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes. Drug Metab Dispos 1996; 24: 955–61PubMed
79.
Arlander E, Ekstrom G, Alm C, et al. Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. Clin Pharmacol Ther 1998; 64: 484–91PubMedCrossRef
80.
81.
Bax NDS, Tucker GT, Lennard MS, et al. The impairment of lignocäine clearance by propranolol: major contribution from enzyme inhibition. Br J Clin Pharmacol 1985; 9: 597–603CrossRef
82.
le Lorrier J, Gredin D, Lapout Y, et al. Pharmacokinetics of lidocaine after intravenous infusions in uncomplicated myocardial infarction. Ann Intern Med 1977; 87: 700–2
83.
Mazoit JX, Lambert C, Berdeaux A, et al. Pharmacokinetics of bupivacaine after short and prolonged infusions in conscious dogs. Anesth Analg 1988; 67: 961–6PubMedCrossRef
84.
Scott DB, Lee A, Fagan D, et al. Acute toxicity of ropivacaine compared with that of bupivacaine. Anesth Analg 1989; 69: 563–9PubMed
85.
Knudsen K, Beckman Suurkula M, Blomberg S, et al. Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers. Br J Anaesth 1997; 78: 507–14PubMedCrossRef
86.
Xu YQ, Pickoff AS, Clarkson CW. Developmental changes in the effects of lidocaine on sodium channels in rat cardiac myocytes. J Pharmacol Exp Ther 1992; 262: 670–6PubMed
87.
Sun LS, Rosen MR. The electrophysiologic effects of bupivacaine on adult, neonatal, and fetal guinea pig papillary muscles. Anesthesiology 1991; 74: 893–39PubMedCrossRef
88.
Giaufre E, Bruguerolle B, Rastello C, et al. New regimen for interpleural block in children. Paediatr Anaesth 1995; 5: 125–8PubMedCrossRef
89.
Elman A, Debaene B, Magny-Metrot C, et al. Interpleural analgesia with bupivacaine following thoracotomy: ineffective results of a controlled study and pharmacokinetics. J Clin Anesth 1993; 5: 118–21PubMedCrossRef
90.
Luz G, Wieser C, Innerhofer P, et al. Free and total bupivacaine plasma concentrations after continuous epidural anaesthesia in infants and children. Paediatr Anaesth 1998; 8: 473–8PubMedCrossRef
91.
Luz G, Innerhofer P, Bachmann B, et al. Bupivacaine plasma concentrations during continuous epidural anesthesia in infants and children. Anesth Analg 1996; 82: 231–4PubMed
Metadata
Title
Pharmacokinetics of Local Anaesthetics in Infants and Children
Authors
Dr Jean-Xavier Mazoit
Bernard J. Dalens
Publication date
01-01-2004
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 1/2004
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200443010-00002